119 related articles for article (PubMed ID: 2677365)
21. Assessment of clinical efficacy and tolerability of terconazole 240-mg vaginal suppositories.
Litschgi M
Gynakol Rundsch; 1985; 25 Suppl 1():59-66. PubMed ID: 4007623
[No Abstract] [Full Text] [Related]
22. Single-day topical treatment of vaginal candidosis: an open evaluation of terconazole 240-mg vaginal suppositories versus isoconazole tablets 600 mg.
Münnich W; Hiltl BP
Gynakol Rundsch; 1985; 25 Suppl 1():90-8. PubMed ID: 4007626
[No Abstract] [Full Text] [Related]
23. Terconazole cream and suppositories: plasma terconazole following vaginal administration.
Kennedy BK; Friedmann N
Gynakol Rundsch; 1985; 25 Suppl 1():26-32. PubMed ID: 4007621
[No Abstract] [Full Text] [Related]
24. Prolonged (3-month) mycological cure rate after boric acid suppositories in diabetic women with vulvovaginal candidiasis.
Ray D; Goswami R; Dadhwal V; Goswami D; Banerjee U; Kochupillai N
J Infect; 2007 Oct; 55(4):374-7. PubMed ID: 17692922
[TBL] [Abstract][Full Text] [Related]
25. Fever and leukocytosis related to terconazole vaginal suppository.
Hyder SS; Manjon JE; Gantz NM
South Med J; 1994 Jul; 87(7):762-3. PubMed ID: 8023214
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Monistat cream (miconazole nitrate 2%) in a reduced regimen for the treatment of vulvovaginal candidiasis.
Sargent EC; Pasquale SA
J Reprod Med; 1977 Aug; 19(2):67-9. PubMed ID: 894647
[TBL] [Abstract][Full Text] [Related]
27. Three-day treatment with butoconazole vaginal suppositories for vulvovaginal candidiasis.
Adamson GD; Brown D; Standard JV; Henzl MR
J Reprod Med; 1986 Feb; 31(2):131-2. PubMed ID: 3514908
[TBL] [Abstract][Full Text] [Related]
28. Butoconazole vaginal cream in the treatment of vulvovaginal candidiasis. Comparison with miconazole nitrate and placebo.
Brown D; Henzl MR; LePage ME; Tsao LL; Izu AE; Walker KA; Adamson GD; Droegmuller W
J Reprod Med; 1986 Nov; 31(11):1045-8. PubMed ID: 3543342
[TBL] [Abstract][Full Text] [Related]
29. The in vitro activity of terconazole against yeasts: its topical long-acting therapeutic efficacy in experimental vaginal candidiasis in rats.
Van Cutsem J
Am J Obstet Gynecol; 1991 Oct; 165(4 Pt 2):1200-6. PubMed ID: 1951575
[TBL] [Abstract][Full Text] [Related]
30. Terconazole, a new triazole antifungal agent.
Cartwrigth RY
Gynakol Rundsch; 1985; 25 Suppl 1():6-11. PubMed ID: 4007624
[No Abstract] [Full Text] [Related]
31. Comparative double-blind evaluation of the efficacy and tolerability of terconazole 240-mg suppository (1 day) and 80-mg suppositories (3 days) versus clotrimazole 200-mg (3 days) in pregnant patients with vulvovaginal candidosis.
Goormans E
Gynakol Rundsch; 1985; 25 Suppl 1():74-82. PubMed ID: 3891540
[No Abstract] [Full Text] [Related]
32. One-day therapy for vaginal candidiasis. A review.
Edelman DA; Grant S
J Reprod Med; 1999 Jun; 44(6):543-7. PubMed ID: 10394549
[TBL] [Abstract][Full Text] [Related]
33. Comparative open evaluation of efficacy and tolerability of terconazole 0.8% cream in a 5-day regimen versus clotrimazole 100-mg tablets in a 6-day regimen.
Wesel S; Benijts G; Ubachs JM; Dogniez B
Gynakol Rundsch; 1985; 25 Suppl 1():67-73. PubMed ID: 4007625
[No Abstract] [Full Text] [Related]
34. One-day treatment of vaginal candidosis: comparison of terconazole 240-mg suppository with clotrimazole 500-mg vaginal tablet.
Grice G; Spencer RC; Steele CE; Kinghorn GR
Gynakol Rundsch; 1985; 25 Suppl 1():83-9. PubMed ID: 3891541
[No Abstract] [Full Text] [Related]
35. Three-day treatment of vulvovaginal candidiasis.
Adamson GD
Am J Obstet Gynecol; 1988 Apr; 158(4):1002-5. PubMed ID: 3364485
[TBL] [Abstract][Full Text] [Related]
36. Single-dose miconazole nitrate vaginal ovule in the treatment of vulvovaginal candidiasis: two single-blind, controlled studies versus miconazole nitrate 100 mg cream for 7 days.
Upmalis DH; Cone FL; Lamia CA; Reisman H; Rodriguez-Gomez G; Gilderman L; Bradley L
J Womens Health Gend Based Med; 2000 May; 9(4):421-9. PubMed ID: 10868615
[TBL] [Abstract][Full Text] [Related]
37. Summary of clinical studies with vaginal formulations of terconazole.
Martinek G
Gynakol Rundsch; 1985; 25 Suppl 1():105-13. PubMed ID: 3891536
[No Abstract] [Full Text] [Related]
38. Treatment of vaginal candidosis with three 80-mg terconazole vaginal suppositories: results of a multicentre study in France.
Nahmanovici C
Gynakol Rundsch; 1985; 25 Suppl 1():52-8. PubMed ID: 3891539
[No Abstract] [Full Text] [Related]
39. Advantages of a 6- to 7-day treatment with 40-mg vaginal suppositories of terconazole against vaginal candidosis: conclusions drawn from a phase II multicentre study in France.
Delecour M
Gynakol Rundsch; 1985; 25 Suppl 1():42-51. PubMed ID: 3891538
[No Abstract] [Full Text] [Related]
40. Effect of investigator bias on clinical trials.
Smith EB
Arch Dermatol; 1989 Feb; 125(2):216-8. PubMed ID: 2913958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
